Journal article
Policy Statement-Modified Recommendations for Use of Palivizumab for Prevention of Respiratory Syncytial Virus Infections
Pediatrics (Evanston), v 124(6), pp 1694-1701
01 Dec 2009
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Palivizumab was licensed in June 1998 by the US Food and Drug Administration for prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients who are at increased risk of severe disease. Safety and efficacy have been established for infants born at or before 35 weeks' gestation with or without chronic lung disease of prematurity and for infants and children with hemodynamically significant heart disease. The American Academy of Pediatrics (AAP) published a policy statement on the use of palivizumab in November 1998 (American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Pediatrics. 1998; 102[5]: 1211-1216) and revised it in December 2003 (American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Pediatrics. 2003; 112[6 pt 1]: 1442-1446), and an AAP technical report on palivizumab was published in 2003 (Meissner HC, Long SS; American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Pediatrics. 2003; 112[6 pt 1]: 1447-1452). On the basis of the availability of additional data regarding seasonality of RSV disease as well as the limitations in available data on risk factors for identifying children who are at increased risk of serious RSV lower respiratory tract disease, AAP recommendations for immunoprophylaxis have been updated in an effort to ensure optimal balance of benefit and cost from this expensive intervention. This statement updates and replaces the 2003 AAP statement and the 2006 Red Book and is consistent with the 2009 Red Book recommendations. Pediatrics 2009; 124: 1694-1701
Metrics
Details
- Title
- Policy Statement-Modified Recommendations for Use of Palivizumab for Prevention of Respiratory Syncytial Virus Infections
- Creators
- Joseph A. BocchiniHenry H. BernsteinJohn S. BradleyMichael T. BradyCarrie L. Byington - Houston MethodistMargaret C. FisherMary P. GlodeMary Anne JacksonHarry L. KeyserlingDavid W. KimberlinWalter A. OrensteinGordon E. SchutzeRodney E. WilloughbyPenelope H. DennehyRobert W. FrenckBeth Bell - Centers for Disease Control and PreventionRobert Bortolussi - Canadian Paediatric SocietyRichard D. Clover - American Academy of Family PhysiciansMarc A. Fischer - Centers for Disease Control and PreventionBruce Gellin - Vaccine Research CenterRichard L. Gorman - National Institutes of HealthR. Douglas Pratt - Food and Drug AdministrationLucia Lee - Food and Drug AdministrationJennifer S. Read - National Institutes of HealthJeffrey R. Starke - American Thoracic SocietyJack Swanson - Society for Ambulatory AnesthesiaCarol J. BakerSarah S. LongLarry K. PickeringEdgar O. LedbetterH. Cody MeissnerLorry G. RubinCaroline HallJennifer Frantz
- Publication Details
- Pediatrics (Evanston), v 124(6), pp 1694-1701
- Publisher
- Amer Acad Pediatrics
- Number of pages
- 8
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pediatrics
- Web of Science ID
- WOS:000272162400026
- Scopus ID
- 2-s2.0-71949099031
- Other Identifier
- 991019335499804721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- International collaboration
- Web of Science research areas
- Pediatrics